Literature DB >> 6761288

Three controlled trials of weight loss with phenylpropanolamine.

S Altschuler, A Conte, M Sebok, R L Marlin, C Winick.   

Abstract

A multisite double-blind study was designed to determine the effectiveness of a phenylpropanolamine-caffeine combination in achieving weight loss. Two-hundred and one obese adult patients were divided into three separate groups in which phenylpropanolamine/caffeine was compared with either placebo (6 weeks), mazindol (6 weeks), or diethylpropion (8 weeks). In these clinical trials, phenylpropanolamine/caffeine proved to be as effective as mazindol and diethylpropion and significantly more effective than placebo in achieving weight loss. Overall, phenylpropanolamine/caffeine had fewer side effects than mazindol and diethylpropion. Its use as an effective anorectic agent in the treatment of obesity is reviewed.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6761288

Source DB:  PubMed          Journal:  Int J Obes


  5 in total

Review 1.  Neurochemical regulators of food behavior for pharmacological treatment of obesity: current status and future prospects.

Authors:  Gayane Sargis Vardanyan; Hasmik Samvel Harutyunyan; Michail Iosif Aghajanov; Ruben Sargis Vardanyan
Journal:  Future Med Chem       Date:  2020-10-12       Impact factor: 3.808

Review 2.  Non-prescription sympathomimetic agents and hypertension.

Authors:  S S Chua; S I Benrimoj
Journal:  Med Toxicol Adverse Drug Exp       Date:  1988 Sep-Oct

Review 3.  Appetite suppressants. A review.

Authors:  T Silverstone
Journal:  Drugs       Date:  1992-06       Impact factor: 9.546

Review 4.  Pharmacotherapy for childhood obesity: present and future prospects.

Authors:  R Sherafat-Kazemzadeh; S Z Yanovski; J A Yanovski
Journal:  Int J Obes (Lond)       Date:  2012-08-28       Impact factor: 5.095

5.  The discriminative stimulus properties of legal, over-the-counter stimulants administered singly and in binary and ternary combinations.

Authors:  D V Gauvin; K R Moore; B D Youngblood; F A Holloway
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.